# CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma

> **NCT00374179** · PHASE1 · COMPLETED · sponsor: **Adnexus, A Bristol-Myers Squibb R&D Company** · enrollment: 40 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** CT-322

## Key facts

- **NCT ID:** NCT00374179
- **Lead sponsor:** Adnexus, A Bristol-Myers Squibb R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-11
- **Final completion:** 2009-02
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2009-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00374179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00374179, "CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00374179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*